Other international projects

COST Action.

The ProteoCure COST Action aims at fostering research and innovation in the field of proteolysis with the goal of manipulating the proteolysis machinery for the development of novel, specific and efficient therapies.
ProteoCure will gather European researchers from the academic, clinical, and industry sectors, interested to develop a knowledge-based network fostering research on this issue. By organizing community-building activities, fostering synergies among European scientists and reinforcing the training of the next generation of European researchers, the Action will allow creation of a large and creative exchange hub focusing on normal and pathologic proteolysis, and on the development of innovative tools modulating the level of specific protein(s). The final aim is to facilitate the translation of novel discoveries into products of clinical and/or economical value.

Project funded by the Institut National du Cancer (INCA) recherche traslationnelle, obtained before the principal investigator joined the CiMUS.

Project funded by a VARIAN research grant, obtained before the principal investigator joined CiMUS.

Project obtained before the principal investigator joined the CiMUS.

Funding: PROGERIA RESEARCH FOUNDATION (USA)

Project funded by a VARIAN research grant, obtained before the principal investigator joined CiMUS

Sustainability of EU-OPENSCREEN ERIC (EU-OS), the European Research Infrastructure Consortium for Chemical Biology, hinges on promoting awareness to academia and industry of its services and data. The EU-funded EU-OPENSCREEN-DRIVE project (DRIVE) will help EU-OS deliver its added value via reuse of data and chemical tools by users around the world. EU-OS provides access to a unique compound collection and a network of screening and chemistry facilities to develop these tools for basic research and therapeutics. DRIVE expands on core services by adding chemoproteomics and fragment screening competencies, by providing access to a database and central office that manages the collection and coordinates project flow and training, and by increasing the competitiveness of European industries through generating innovation in health research. 

Coordinator: European Infrastructure Of Open Screening Platforms For Chemical Biology European Research Infrastucture Consortium (Eu-Openscreen Eric) (Germany) 

Partners: Ustav Molekularni Genetiky Akademie Ved Ceske Republiky Verejna Vyzkumna Instituce (Czech Republic), Univerzita Palackeho V Olomouci (Czech Republic), Helmholtz-Zentrum Fur Infektionsforschung GMBH (Germany), Fraunhofer Gesellschaft Zur Froderung Der Angewandten Forschung EV (Germany), Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía (Spain), Fundación de la Comunidad Valenciana Centro de Investigación Príncipe Felipe (Spain), Universidad Santiago de Compostela (Spain), Helsingin Yliopisto (Finland), Universitetet I Bergen (Norway), Universitetet I Tromsoe - Norges Arktiske Univesitet (Norway), Universitetet I Oslo (Norway), Sintef AS (Norway), Instytut Biologii Medycznej Polskiej Akademii Nauk (Poland), Instytut Chemii Bioorganicznej Polskiej Akademii Nauk (Poland), Masarykova Univerzita (Czech Republic), Danmarks Tekniske Universitet (Denmark), Agencia Estatal Consejo Superior de Investigaciones Científicas (Spain), Latvijas Organiskas Sintezes Instituts (Latvia), Instytut Biochemii I Biofizyki Polskiej Akademii Nauk (Poland), Fundació Institut Mar D Investigacions Mediques IMIM (Spain), CSC-TIETEEN Tietotekniikan Keskus OY (Finland), European Molecular Biology Laboratory (Germany), Hochschule Mannheim (Germany), Technische Universitaet Muenchen (Germany), National Center For Scientific Research "Demokritos" (Greece), Karolinska Institutet (Sweden), Instituto de Biologia Molecular e Celular IBMC (Portugal), Academisch Ziekenhuis Leiden (The Netherlands), Weizmann Institute of Science (Israel), Termeszettudomanyi Kutatokozpont (Hungary), Institutul de Chimie Coriolan Dragulescu (Romania), Ecole Polytechnique Federale de Lausanne (Switzerland) and Forschungsverbund Berlin EV (Germany).

COST - Action.
Despite significant progress in understanding the individual components, signal transduction as a whole is not fully understood. Fundamental questions remain regarding how different signalling pathways are activated and modulated in precise and reproducible ways. Filling this gap in knowledge is absolutely necessary to advance the next generation of drugs that will achieve therapeutic efficacy while minimizing side effects. A prime example of this research challenge is the large family of G protein-coupled receptors (GPCRs), which are the target of more than a third of all marketed drugs. The COST Action ERNEST (European Research Network on Signal Transduction) will tackle this challenge by uniting scientists from different disciplines spanning the molecular, cellular, physiological, and clinical perspectives. This network of diverse investigators will be uniquely able to synergistically develop an unprecedented comprehensive understanding of signal transduction that will advance drug design efforts in Europe, for the benefit of societies and human health worldwide.

COST - Action.

The proposed COST actions aim to foster the development of the emerging field of epitranscriptomics in Europe. EPITRAN is based on the premise that by understanding the role of RNA modifications in physiology and pathology, powerful new disease biomarkers and drug targets could be identified. This, in turn, will lead to the development of a whole new class of diagnostic tools and targeted therapies, with a particular focus on cancer treatment. Furthermore, a mechanistic understanding of this set of phenomena will deepen our knowledge of the contribution of post-transcriptional regulation of gene expression to the proteome and thus phenotype variation. This COST action will accelerate discoveries in the field of epitranscriptomics and contribute to realising this vision through collaborative efforts, data sharing and mobility-based learning opportunities.

COST - Action.

In relation to human health, several examples highlight the importance of the processes involved in autophagy as therapeutic targets, as modulation of autophagy has a recognised potential to combat cancer, lupus erythematosus (already in phase III), neurodegeneration and infections, as well as a key strategy to slow down age-related tissue deterioration. On the biotechnological front, modulation of autophagy enables innovative applications for optimal agri-food production or alternative energy sources from microalgae. These and broader perspectives will be enhanced by TRANSAUTOPHAGY, a consortium that serves as a platform for companies, stakeholders and researchers from various disciplines. This project seeks cooperation to generate multidisciplinary advances in the regulation of autophagy, and to use this knowledge for biomedical and biotechnological purposes.